Disappointment Over the Uptake of Humira Biosimilars | Asembia 2024
In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about the disappointment surrounding the uptake of Humira biosimilars.
In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium talks about the disappointment surrounding the uptake of Humira biosimilars.
Lockhart spoke about biosimilars at an Asembia 2024 session yesterday but was interviewed earlier this month by Managed Healthcare Executive.
"I think the fact that we haven't seen much uptake of the adalimumab biosimilars yet is disappointing," she said in the interview. "Although at the same time, it seems to be following a pattern that we've seen with a lot of biosimilars especially early on in their availability."
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024
May 2nd 2024Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Read More
